Outpatient treatment in german adolescents with depression: An analysis of nationwide health insurance data

Pharmacoepidemiology and Drug Safety

Volumn 21, Issue 9, 2012, Pages 972-979

  Hoffmann, Falk ^a   Glaeske, Gerd ^a   Petermann, Franz ^a   Bachmann, Christian J ^b  

^a UNIVERSITY OF BREMEN   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Adolescents; Antidepressants; Depression; Outpatient; Statutory health insurance

Indexed keywords

CITALOPRAM; FLUOXETINE; HYPERICUM EXTRACT; MIRTAZAPINE;

ADJUSTMENT DISORDER; ADOLESCENT; ARTICLE; DEPRESSION; FEMALE; HEALTH INSURANCE; HUMAN; HYPERICUM; MAJOR CLINICAL STUDY; MALE; OFF LABEL DRUG USE; OUTPATIENT CARE; PRESCRIPTION; PREVALENCE; PRIORITY JOURNAL; PSYCHOTHERAPY;

ADOLESCENT; AGE FACTORS; AMBULATORY CARE; ANTIDEPRESSIVE AGENTS; CHILD; COMBINED MODALITY THERAPY; CROSS-SECTIONAL STUDIES; DATABASES, FACTUAL; DEPRESSIVE DISORDER; FEMALE; GERMANY; GUIDELINE ADHERENCE; HUMANS; MALE; PRACTICE GUIDELINES AS TOPIC; PSYCHOTHERAPY; SEX FACTORS;

EID: 84865863413     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.3295     Document Type: Article

References (52)

1. Costello EJ, Erkanli A, Angold A. Is there an epidemic of child or adolescent depression? J Child Psychol Psychiatry 2006; 47: 1263-1271.
2. Essau CA, Lewinsohn PM, Seeley JR, Sasagawa S. Gender differences in the developmental course of depression. J Affect Disord 2010; 127(1-3): 185-190.
3. Gore FM, Bloem PJ, Patton GC, et al, Global burden of disease in young people aged 10-24years: a systematic analysis. Lancet 2011; 377(9783): 2093-2102.
4. Costello EJ, Foley DL, Angold A. 10-year research update review: the epidemiology of child and adolescent psychiatric disorders: II. Developmental epidemiology. J Am Acad Child Adolesc Psychiatry 2006; 45(1): 8-25.
5. Essau CA. Comorbidity of depressive disorders among adolescents in community and clinical settings. Psychiatry Res 2008; 158(1): 35-42.
6. Petermann F. Epidemiology of mental disorders in children and adolescents. A critical review. Kindh Entwickl 2005; 14(1): 48-59.
7. Curry J, Silva S, Rohde P, et al, Recovery and recurrence following treatment for adolescent major depression. Arch Gen Psychiatry 2011; 68(3): 263-269.
8. Fombonne E, Wostear G, Cooper V, Harrington R, Rutter M. The Maudsley long-term follow-up of child and adolescent depression. 1. Psychiatric outcomes in adulthood. Br J Psychiatry 2001; 179: 210-217.
9. Mühlbauer B, Janhsen K, Pichler J, Schoettler P. Off-label use of prescription drugs in childhood and adolescence: an analysis of prescription patterns in Germany. Dtsch Arztebl Int 2009; 106(3): 25-31.
10. Deutsche Gesellschaft für Kinder- und Jugendpsychiatrie (DGKJP). Leitlinien zu Diagnostik und Therapie von psychischen Störungen im Säuglings-, Kindes- und Jugendalter. Deutscher Ärzte-Verlag: Köln, 2007.
11. NICE. Depression in children and young people: identification and management in primary, community and secondary care (NICE guideline). National Institute for Health and Clinical Excellence, 2005. www.nice.org.uk. Updated 2011.
12. Birmaher B, Brent D; AACAP Work Group on Quality Issues, et al, Practice Parameter for the Assessment and Treatment of Children and Adolescents With Depressive Disorders. J Am Acad Child Adolesc Psychiatry 2007; 46(11): 1503-1526.
13. Hegerl U, Allgaier AK, Henkel V, Mergl R. Can effects of antidepressants in patients with mild depression be considered as clinically significant? J Affect Disord 2012; 138(3): 183-191.
14. Volkers AC, Heerdink ER, van Dijk L. Antidepressant use and off-label prescribing in children and adolescents in Dutch general practice (2001-2005). Pharmacoepidemiol Drug Saf 2007; 16: 1054-1062.
15. Clavenna A, Rossi E, Derosa M, Bonati M. Use of psychotropic medications in Italian children and adolescents. Eur J Pediatr 2007; 166(4): 339-347.
16. Foulon V, Svala A, Koskinen H, Chen TF, Saastamoinen LK, Bell JS. Impact of regulatory safety warnings on the use of antidepressants among children and adolescents in Finland. J Child Adolesc Psychopharmacol 2010; 20(2): 145-150.
17. Olfson M, Marcus SC. National patterns in antidepressant medication treatment. Arch Gen Psychiatry 2009; 66(8): 848-856.
18. Zoëga H, Baldursson G, Hrafnkelsson B, Almarsdóttir AB, Valdimarsdóttir U, Halldórsson M. Psychotropic drug use among Icelandic children: a nationwide population-based study. J Child Adolesc Psychopharmacol 2009; 19(6): 757-764.
19. Katz LY, Kozyrskyj AL, Prior HJ, Enns MW, Cox BJ, Sareen J. Effect of regulatory warnings on antidepressant prescription rates, use of health services and outcomes among children, adolescents and young adults. CMAJ 2008; 178(8): 1005-1011.
20. Zito JM, Tobi H, de Jong-van den Berg LT, et al, Antidepressant prevalence for youths: a multi-national comparison. Pharmacoepidemiol Drug Saf 2006; 15: 793-798.
21. Fegert JM, Kölch M, Zito JM, Glaeske G, Janhsen K. Antidepressant use in children and adolescents in Germany. J Child Adolesc Psychopharmacol 2006; 16: 197-206.
22. Gemeinsame Stellungnahme der Deutschen Gesellschaft für Psychiatrie, Psychotherapie und Nervenheilkunde (DGPPN) und der Arbeitsgemeinschaft für Neuropsychopharmakologie und Pharmakopsychiatrie (AGNP) Zielvereinbarung 2005 zwischen GKV und KV-Hamburg: Ausgabensenkung um 1% u.a. bei Antidepressiva blockiert Teilhabe der Kranken am Fortschritt. psychoneuro 2005; 31(9): 449-450.
23. Bauer M, Monz BU, Montejo AL, et al, Prescribing patterns of antidepressants in Europe: results from the Factors Influencing Depression Endpoints Research (FINDER) study. Eur Psychiatry 2008; 23(1): 66-73.
24. Evans-Lacko SE, dosReis S, Kastelic EA, Paula CS, Steinwachs DM. Evaluation of guideline-concordant care for bipolar disorder among privately insured youth. Prim Care Companion J Clin Psychiatry 2010; 12(3). PCC.09m00837.
25. Skaer TL, Sclar DA, Robison LM. Trends in prescriptions for antidepressant pharmacotherapy among US children and adolescents diagnosed with depression, 1990 through 2001: an assessment of accordance with treatment recommendations from the American Academy of Child and Adolescent Psychiatry. Clin Ther 2009; 31(Pt 1): 1478-1487.
26. Mann JJ, Emslie G, Baldessarini RJ, et al, ACNP Task Force report on SSRIs and suicidal behavior in youth. Neuropsychopharmacology 2006; 31(3): 473-492.
27. Bergen H, Hawton K, Murphy E, et al, Trends in prescribing and self-poisoning in relation to UK regulatory authority warnings against use of SSRI antidepressants in under-18-year-olds. Br J Clin Pharmacol 2009; 68(4): 618-629.
28. Nemeroff CB, Kalali A, Keller MB, et al, Impact of publicity concerning pediatric suicidality data on physician practice patterns in the United States. Arch Gen Psychiatry 2007; 64(4): 466-472.
29. Dean AJ, Hendy A, McGuire T. Antidepressants in children and adolescents - changes in utilisation after safety warnings. Pharmacoepidemiol Drug Saf 2007; 16(9): 1048-1053.
30. Treatment for Adolescents With Depression Study (TADS) Team, March J, Silva S, et al, The Treatment for Adolescents With Depression Study (TADS): outcomes over 1year of naturalistic follow-up. Am J Psychiatry 2009; 166(10): 1141-1149.
31. Curry J, Silva S, Rohde P, et al, Recovery and recurrence following treatment for adolescent major depression. Arch Gen Psychiatry 2011; 68(3): 263-269.
32. Tsapakis EM, Soldani F, Tondo L, Baldessarini RJ. Efficacy of antidepressants in juvenile depression: meta-analysis. Br J Psychiatry 2008; 193(1): 10-17.
33. Alonso-Coello P, Irfan A, Solà I, et al, The quality of clinical practice guidelines over the last two decades: a systematic review of guideline appraisal studies. Qual Saf Health Care 2010; 19(6): e58.
34. Gaebel W, Weinmann S, Sartorius N, Rutz W, McIntyre JS. Schizophrenia practice guidelines: international survey and comparison. Br J Psychiatry 2005; 187: 248-255.
35. Goodyer I, Dubicka B, Wilkinson P, et al, Selective serotonin reuptake inhibitors (SSRIs) and routine specialist care with and without cognitive behaviour therapy in adolescents with major depression: randomised controlled trial. BMJ 2007; 335(7611): 142.
36. Soh N, Walter G. Complementary medicine for psychiatric disorders in children and adolescents. Curr Opin Psych 2008; 21(4): 350-355.
37. Kölch M, Allroggen M, Fegert JM. Off-Label-Use von Psychopharmaka in der Kinder- und Jugendpsychiatrie. Ein andauerndes ethisches, medizinisches und rechtliches Problem [Off-label use in child and adolescent psychiatry. An ongoing ethical, medical and legal problem]. Nervenarzt 2009; 80(7): 789-796.
38. Clavenna A, Andretta M, Pilati P, et al, Antidepressant and antipsychotic use in an Italian pediatric population. BMC Pediatr 2011; 11: 40.
39. Lee E, Teschemaker AR, Johann-Liang R, et al, Off-label prescribing patterns of antidepressants in children and adolescents. Pharmacoepidemiol Drug Saf 2012; 21(2): 137-44.
40. Lehmkuhl G, Köster I, Schubert I. Ambulante Versorgung kinder- und jugendpsychiatrischer Störungen - Daten einer versichertenbezogenen epidemiologischen Studie [Outpatient care for child and adolescent psychiatric disorders - data from an insuree-related epidemiological study]. Prax Kinderpsychol Kinderpsychiatr 2009; 58(3): 170-185.
41. International Association for Child and Adolescent Psychiatry and Allied Professions (IACAPAP). Declaration of Budapest 1992: Assuring the Mental Health of Children. 1992. available on: http://iacapap.org/wp-content/uploads/Budapest1992.pdf (accessed 22 December 2011).
42. Schneeweiss S. Developments in post-marketing comparative effectiveness research. Clin Pharmacol Ther 2007; 82: 143-156.
43. Hoffmann F, Icks A. Diabetes prevalence based on health insurance claims: large differences between companies. Diabet Med 2011; 28(8): 919-923.
44. Hoffmann F, Icks A. Unterschiede in der Versichertenstruktur von Krankenkassen und deren Auswirkungen für die Versorgungsforschung: Ergebnisse des Bertelsmann-Gesundheitsmonitors [Structural Differences between Health Insurance Funds and their Impact on Health Services Research. Results from the Bertelsmann Health-Care Monitor.] Gesundheitswesen. 2011 Jul 13 [Epub ahead of print].
45. Richardson LP, Russo JE, Lozano P, McCauley E, Katon W. Factors associated with detection and receipt of treatment for youth with depression and anxiety disorders. Acad Pediatr 2010; 10(1): 36-40.
46. Aromaa E, Tolvanen A, Tuulari J, Wahlbeck K. Personal stigma and use of mental health services among people with depression in a general population in Finland. BMC Psychiatry 2011; 11: 52.
47. Hämäläinen J, Isometsä E, Laukkala T, et al, Use of health services for major depressive episode in Finland. J Affect Disord 2004; 79(1-3): 105-112.
48. Woldu H, Porta G, Goldstein T, et al, Pharmacokinetically and clinician-determined adherence to an antidepressant regimen and clinical outcome in the TORDIA trial. J Am Acad Child Adolesc Psychiatry 2011; 50(5): 490-498.
49. Fontanella CA, Bridge JA, Marcus SC, Campo JV. Factors associated with antidepressant adherence for medicaid-enrolled children and adolescents. Ann Pharmacother 2011; 45(7-8): 898-909.
50. Kölch M, Prestel A, Singer H, et al, Psychotropic medication in children and adolescents in Germany: prevalence, indications, and psychopathological patterns. J Child Adolesc Psychopharmacol 2009; 19(6): 765-770.
51. Tournier M, Greenfield B, Galbaud du Fort G, et al, Patterns of antidepressant use in Quebec children and adolescents: trends Volkers AC, Heerdink ER, van Dijk L. Antidepressant use and off-label prescribing in children and adolescents in Dutch general practice (2001-2005). Pharmacoepidemiol Drug Saf 2007; 16: 1054-1062.
52. Acquaviva E, Legleye S, Auleley GR, Deligne J, Carel D, Falissard B. Psychotropic medication in the French child and adolescent population: prevalence estimation from health insurance data and national self-report survey data. BMC Psychiatry 2009; 9: 72.